Pharsight

Xcopri generic

Xcopri is an anticonvulsant drug owned by Sk Life Science. The drug contains the active ingredient cenobamate and was first authorized for market use on March 10, 2020. In its various dosage forms, Xcopri can be administered orally as a tablet. The drug holds a total of 2 patents, none of which have expired as of now.

When will Xcopri generic be available?

The generic release of Xcopri is anticipated after June 16, 2039, marking the expiry date of its last patent. Drug patent challenges can be filed against Xcopri starting from March 10, 2024. The release of Xcopri's generic versions might be sped up by Para IV filings.

Xcopri uses

Xcopri, with its active ingredient cenobamate, is used for the treatment of partial onset seizures. The drug can be co-administered with phenobarbital and/or phenytoin to enhance its effectiveness in controlling seizures.

Xcopri patent expiration

Xcopri currently holds 2 patents. The latest patent, titled 'Use of [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate in combination therapy,' is set to expire on June 16, 2039. Another patent titled 'Neurotherapeutic azole compounds' will expire earlier on October 30, 2032. With these patent expirations, Xcopri generic release is expected after June 16, 2039. Below are the details of the patent:

Xcopri dosage

Want to ask something?